These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22389472)

  • 1. Inhibition of OCTN2-mediated transport of carnitine by etoposide.
    Hu C; Lancaster CS; Zuo Z; Hu S; Chen Z; Rubnitz JE; Baker SD; Sparreboom A
    Mol Cancer Ther; 2012 Apr; 11(4):921-9. PubMed ID: 22389472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2.
    Todesco L; Bur D; Brooks H; Török M; Landmann L; Stieger B; Krähenbühl S
    Cell Mol Life Sci; 2008 May; 65(10):1596-608. PubMed ID: 18408886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.
    Lancaster CS; Hu C; Franke RM; Filipski KK; Orwick SJ; Chen Z; Zuo Z; Loos WJ; Sparreboom A
    Clin Cancer Res; 2010 Oct; 16(19):4789-99. PubMed ID: 20858838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition.
    Inano A; Sai Y; Kato Y; Tamai I; Ishiguro M; Tsuji A
    Drug Metab Pharmacokinet; 2004 Jun; 19(3):180-9. PubMed ID: 15499185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
    Ohashi R; Tamai I; Yabuuchi H; Nezu JI; Oku A; Sai Y; Shimane M; Tsuji A
    J Pharmacol Exp Ther; 1999 Nov; 291(2):778-84. PubMed ID: 10525100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2.
    Wagner CA; Lükewille U; Kaltenbach S; Moschen I; Bröer A; Risler T; Bröer S; Lang F
    Am J Physiol Renal Physiol; 2000 Sep; 279(3):F584-91. PubMed ID: 10966938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Na(+)-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney.
    Tamai I; China K; Sai Y; Kobayashi D; Nezu J; Kawahara E; Tsuji A
    Biochim Biophys Acta; 2001 Jun; 1512(2):273-84. PubMed ID: 11406104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2.
    Tamai I; Ohashi R; Nezu J; Yabuuchi H; Oku A; Shimane M; Sai Y; Tsuji A
    J Biol Chem; 1998 Aug; 273(32):20378-82. PubMed ID: 9685390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier.
    Friedrich A; Prasad PD; Freyer D; Ganapathy V; Brust P
    Brain Res; 2003 Apr; 968(1):69-79. PubMed ID: 12644265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart.
    Iwata D; Kato Y; Wakayama T; Sai Y; Kubo Y; Iseki S; Tsuji A
    Drug Metab Pharmacokinet; 2008; 23(3):207-15. PubMed ID: 18574325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations.
    Toh DS; Murray M; Pern Tan K; Mulay V; Grewal T; Lee EJ; Zhou F
    Biochem Pharmacol; 2011 Dec; 82(11):1692-9. PubMed ID: 21864509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment.
    Ohnishi S; Okamura N; Sakamoto S; Hasegawa H; Norikura R; Kanaoka E; Takahashi K; Horie K; Sakamoto K; Baba T
    Drug Metab Pharmacokinet; 2008; 23(4):293-303. PubMed ID: 18762717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5).
    Visentin M; Gai Z; Torozi A; Hiller C; Kullak-Ublick GA
    Drug Metab Dispos; 2017 Dec; 45(12):1240-1244. PubMed ID: 28986476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
    Ohashi R; Tamai I; Nezu Ji J; Nikaido H; Hashimoto N; Oku A; Sai Y; Shimane M; Tsuji A
    Mol Pharmacol; 2001 Feb; 59(2):358-66. PubMed ID: 11160873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of OCTN2 and OCTN3 in the apical membrane of rat renal cortex and medulla.
    Cano MM; Calonge ML; Ilundain AA
    J Cell Physiol; 2010 May; 223(2):451-9. PubMed ID: 20112288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
    Ganapathy ME; Huang W; Rajan DP; Carter AL; Sugawara M; Iseki K; Leibach FH; Ganapathy V
    J Biol Chem; 2000 Jan; 275(3):1699-707. PubMed ID: 10636865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model.
    Okura T; Kato S; Deguchi Y
    Drug Metab Pharmacokinet; 2014; 29(1):69-74. PubMed ID: 23877104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans.
    Morand R; Todesco L; Donzelli M; Fischer-Barnicol D; Mullen PJ; Krähenbühl S
    Ther Drug Monit; 2012 Aug; 34(4):406-14. PubMed ID: 22743351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency.
    Filippo CA; Ardon O; Longo N
    Biochim Biophys Acta; 2011 Mar; 1812(3):312-20. PubMed ID: 21126579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cationic polyrotaxanes effectively inhibit uptake via carnitine/organic cationic transporters without cytotoxicity.
    Utsunomiya H; Katoono R; Yui N; Sugiura T; Kubo Y; Kato Y; Tsuji A
    Macromol Biosci; 2008 Jul; 8(7):665-9. PubMed ID: 18366149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.